跳至主要内容
临床试验/NCT05755516
NCT05755516已完成不适用

Efficacy and Safety of the Self-expanding Intracranial Stent (Tonbridge) for Endovascular Treatment of Intracranial Aneurysms: A Prospective, Multi-center, Randomized, Open, Parallel Positive Controlled, Non-inferiority Trial

Ton-Bridge Medical Tech. Co., Ltd28 个研究点 分布在 1 个国家目标入组 204 人开始时间: 2023年2月14日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
204
试验地点
28
主要终点
Successful occlusion rate of aneurysms at 6 months

研究概览

简要总结

The purpose of this study is to assess the efficacy and safety of Self-expanding Intracranial Stent (Tonbridge), by comparing the data obtained from Self-expanding Intracranial Stent (Zhuhai Tonbridge Medical Tech. Co., Ltd.) and LVIS/LVIS Jr. (MicroVention Europe SARL) for endovascular treatment of intracranial aneurysms.

详细描述

This is a prospective, multi-center, randomized, open, parallel positive controlled, non-inferiority trial. This clinical trial is conducted at more than 2 centers in China, and patients who intend to be treated with stent-assisted coiling for intracranial aneurysms are enrolled. Eligible patients are randomized into experimental group using Self-expanding Intracranial Stent (Tonbridge) or control group using LVIS and LVIS Jr. (MicroVention) in a 1:1 ratio. The purpose of this study is to evaluate the effectiveness and safety of the Self-expanding Intracranial Stent (Tonbridge).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18 to 80 years, any gender;
  • Diagnosed as intracranial aneurysm and the subject is assessed as suitable for stent-assisted coiling;
  • Subject or guardian is able to understand the purpose of study, shows sufficient compliance with the study protocol and provides a signed informed consent form.

排除标准

  • Aneurysm rupture within 30 days before enrollment;
  • Diagnosed as blood blister-like aneurysm, pseudoaneurysm, infected aneurysm, or aneurysm related to arteriovenous malformations;
  • Conditions that are not appropriate for stent delivery and deployment judged by investigators (severe stenosis of parent artery, severe tortuosity of parent artery, stent failing to reach the lesion, stent in the target lesion of parent artery, etc.);
  • Modified Rankin Scale (mRS) score ≥3;
  • Heart, lung, liver and renal failure or other severe diseases (intracranial tumor, systemic infection, disseminated intravascular coagulation, myocardial infarction within 12 months before enrollment, history of severe psychosis, severe stenosis or occlusion of cerebral feeding artery, etc.);
  • Major surgery within 30 days before enrollment;
  • Known coagulation dysfunction or contraindication to anticoagulant and antiplatelet therapy;
  • Known allergy to nickel-titanium alloy metal materials;
  • Life expectancy <12 months;
  • Pregnant or breastfeeding women;
  • Subject has participated in other drug or medical device clinical trials within 1 month before signing informed consent;
  • Other conditions judged by the investigators as unsuitable for enrollment.

结局指标

主要结局

Successful occlusion rate of aneurysms at 6 months

时间窗: 6 months±30 days post-procedure

Successful occlusion is defined as complete occlusion or neck remnant (Raymond-Roy class I or Ⅱ), which is diagnosed by cerebrovascular DSA at 6 months post-procedure.

次要结局

  • Incidence of serious adverse events(180±30 days, 360±30 days post-procedure)
  • Retreatment rate(180±30 days, 360±30 days post-procedure)
  • Incidence of parent artery occlusion in target area(180±30 days, 360±30 days post-procedure)
  • Incidence of stroke(30±7 days, 360±30 days post-procedure)
  • Device success rate(intra-procedure)
  • All-cause mortality(30±7 days, 360±30 days post-procedure)
  • Immediate successful occlusion rate of aneurysms(intra-procedure)
  • Incidence of adverse events(180±30 days, 360±30 days post-procedure)
  • Recurrence rate of aneurysms at 6 months(6 months±30 days post-procedure)
  • Operation satisfaction rate(intra-procedure)
  • Incidence of parent artery stenosis (>50%) in target area(180±30 days, 360±30 days post-procedure)
  • Incidence of device deficiency(intra-procedure, 180±30 days post-procedure)

研究者

发起方
Ton-Bridge Medical Tech. Co., Ltd
申办方类型
Industry
责任方
Sponsor

研究点 (28)

Loading locations...

相似试验